Racial disparities in cardiovascular manifestations among patients with sickle cell trait: analysis of national inpatient sample data (2016–2020)

IF 2.4 3区医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2025-03-20 DOI:10.1007/s00277-025-06306-0

Praneeth Reddy Keesari, Charan Thej Reddy Vegivinti, Medha Rajamanuri, Ahmad Mustafa, Ngowari Pokima, Lauren Haley White, Hasnain Chaudhry, Chamberline E Ozigbu, Khairul A Siddiqi, Suzanne El-Sayegh, Meekoo Dhar, Ugochi Olivia Ogu

{"title":"Racial disparities in cardiovascular manifestations among patients with sickle cell trait: analysis of national inpatient sample data (2016–2020)","authors":"Praneeth Reddy Keesari, Charan Thej Reddy Vegivinti, Medha Rajamanuri, Ahmad Mustafa, Ngowari Pokima, Lauren Haley White, Hasnain Chaudhry, Chamberline E Ozigbu, Khairul A Siddiqi, Suzanne El-Sayegh, Meekoo Dhar, Ugochi Olivia Ogu","doi":"10.1007/s00277-025-06306-0","DOIUrl":null,"url":null,"abstract":"<div><p>Sickle cell trait (SCT) is a condition that affects up to 3 million individuals and 10% of African Americans (AA) in the United States (U.S.). Although often believed to be benign, the true burden of the condition remains understudied. Data is also lacking regarding the racial disparities in SCT and if African American individuals with SCT are at increased cardiovascular risk compared to individuals of other races. Using the National Inpatient Sample (NIS) database, we investigated cardiovascular outcomes in AA individuals with SCT compared to other racial groups. Our study reported statistically significant higher odds of acute heart failure in AA individuals with SCT (Adjusted OR: 1.39 (<i>p</i> < 0.01, 95% CI: 1.13–1.71). Further studies investigating the racial disparities and cardiovascular risk among individuals with SCT are warranted to measure the causal effects.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 3","pages":"1501 - 1506"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-025-06306-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-025-06306-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Sickle cell trait (SCT) is a condition that affects up to 3 million individuals and 10% of African Americans (AA) in the United States (U.S.). Although often believed to be benign, the true burden of the condition remains understudied. Data is also lacking regarding the racial disparities in SCT and if African American individuals with SCT are at increased cardiovascular risk compared to individuals of other races. Using the National Inpatient Sample (NIS) database, we investigated cardiovascular outcomes in AA individuals with SCT compared to other racial groups. Our study reported statistically significant higher odds of acute heart failure in AA individuals with SCT (Adjusted OR: 1.39 (p < 0.01, 95% CI: 1.13–1.71). Further studies investigating the racial disparities and cardiovascular risk among individuals with SCT are warranted to measure the causal effects.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

镰状细胞特征患者心血管表现的种族差异：2016-2020年全国住院患者样本数据分析

镰状细胞特征（SCT）是一种影响美国多达300万人和10%的非洲裔美国人（AA）的疾病。虽然通常被认为是良性的，但这种疾病的真正负担仍未得到充分研究。关于SCT的种族差异以及接受SCT的非裔美国人是否比其他种族的人有更高的心血管风险的数据也缺乏。使用国家住院患者样本（NIS）数据库，我们调查了AA患者与其他种族人群进行SCT的心血管结局。我们的研究报告了具有统计学意义的急性心力衰竭的风险在AA个体中有较高的SCT(校正OR: 1.39 (p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.